|Home | About | Journals | Submit | Contact Us | Français|
The folate enzyme, FDH (10-formyltetrahydrofolate dehydrogenase, ALDH1L1), a metabolic regulator of proliferation, activates p53-dependent G1 arrest and apoptosis in A549 cells. In the present study, we have demonstrated that FDH-induced apoptosis is abrogated upon siRNA knockdown of the p53 downstream target PUMA. Conversely, siRNA knockdown of p21 eliminated FDH-dependent G1 arrest and resulted in an early apoptosis onset. The acceleration of FDH-dependent apoptosis was even more profound in another cell line, HCT116, in which the p21 gene was silenced through homologous recombination (p21−/− cells). In contrast to A549 cells, FDH caused G2 instead of G1 arrest in HCT116 p21+/+ cells; such an arrest was not seen in p21-deficient (HCT116 p21−/−) cells. In agreement with the cell cycle regulatory function of p21, its strong accumulation in nuclei was seen upon FDH expression. Interestingly, our study did not reveal DNA damage upon FDH elevation in either cell line, as judged by comet assay and the evaluation of histone H2AX phosphorylation. In both A549 and HCT116 cell lines, FDH induced a strong decrease in the intracellular ATP pool (2-fold and 30-fold, respectively), an indication of a decrease in de novo purine biosynthesis as we previously reported. The underlying mechanism for the drop in ATP was the strong decrease in intracellular 10-formyltetrahydrofolate, a substrate in two reactions of the de novo purine pathway. Overall, we have demonstrated that p21 can activate G1 or G2 arrest in the absence of DNA damage as a response to metabolite deprivation. In the case of FDH-related metabolic alterations, this response delays apoptosis but is not sufficient to prevent cell death.
The p21 (WAF1/Cip1) protein is an inhibitor of cyclin-dependent kinases1-3 and a predominant member of the Cip/Kip family of Cdk inhibitors.4,5 As a Cdk inhibitor, p21 controls cell cycle progression and negatively regulates cellular proliferation.2,3 In support of the role of p21 in controlling the cell cycle, p21 knockout mice, while undergoing normal development, lack the ability to arrest in G1 in response to DNA damage or nucleotide pool perturbation.6 The p21 gene is also one of the main transcriptional targets of the p53 tumor suppressor7 and is required for p53-dependent G1 and G2 cell cycle arrest.8-10 For example, DNA damage produced by ionizing radiation or by treatment with drugs such as adriamycin induces p53 and p21, leading to G1 and/or G2 arrest.10-12
The cell cycle arrest is a common cellular response to DNA damage and is viewed as a delay period in DNA replication during which the cell can attempt to repair the damage. If this attempt fails, cell death pathways will be activated. Based on this paradigm, the p21-induced cell cycle arrest is considered as an antiapoptotic response.13 Numerous studies support this notion, indicating that inhibition of cell cycle progression by elevated levels of p21 prevents apoptosis.13-17 Likewise, the loss of p21 often enhances apoptosis induced by certain stimuli.18 Contrary to such studies, some reports suggested that p21 could also have a proapoptotic role. For example, ectopic expression of p21 in the p53-defective human ovarian adenocarcinoma cell line SKOV3 not only makes the cells more susceptible to apoptosis but also enhances the cytotoxic effect of cisplatin.19 It has been also reported that p21 is required for sodium butyrate–induced apoptosis in MCF-7 cells.20 In line with this observation, it has been demonstrated that elevated p21 increases expression of proapoptotic protein Bax and accelerates apoptosis in C6-ceramide–treated Hep3B cells.21 Of note, p21 can directly regulate apoptosis independently of its function in the cell cycle control.16,17 Overall, p21 perhaps can evoke either proapoptotic or antiapoptotic responses, depending on the cell type, stress stimuli, and accompanying signaling events.13,15,22
In cell culture experiments, p21 is often up-regulated in response to treatment with anticancer drugs.22 Among these drugs are antifolates, a class of antimetabolites used in the treatment of cancer since the late 1940s.23 Several studies have demonstrated that MTX (inhibitor of dihydrofolate reductase), AG2034 (inhibitor of glycinamid ribonucleotide formyltransferase), and pemetrexed (inhibits both of the above enzymes plus thymidylate synthase, TS) all result in the increase of p21 levels.24-27 These drugs target folate metabolism, ultimately inhibiting de novo purine and TMP biosynthesis. It has been also reported that sensitivity to 5-FU, another TS inhibitor, was increased in cells upon elevation of p21 levels.28 This effect was associated with decreased expression of TS due to transcriptional regulation of the TS gene through the p21/CDK axis.29 A connection between folate metabolism and p21 was also demonstrated in the study by Crott et al., in which a decrease of media folate was accompanied by a concomitant increase in the p21 transcript levels.30
Elevation of p21 was also observed in studies of FDH (10-formyltetrahydrofolate dehydrogenase, ALDH1L1), a major folate enzyme controlling the overall flux of one-carbon groups through the folate pool.31 The enzyme functions as a metabolic regulator, which removes carbon groups, in the form of CO2, from the reduced folate pool, thus diverting them from biosynthetic pathways.32,33 This function results from FDH-catalyzed reaction of the conversion of 10-formyltetrahydrofolate (10-fTHF) to tetrahydrofolate (THF) and CO2 in a NADP+-dependent manner.33 FDH, being abundant in normal tissues, is commonly down-regulated or silenced in cancers.34 One of the main mechanisms of such regulation is FDH gene (ALDH1L1) promoter methylation.35 In our previous experiments, the expression of the enzyme in FDH-deficient A549 cells resulted in G1 cell cycle arrest and p53-dependent apoptosis.31 These effects are likely the result of a strong depletion of intracellular purine pools associated with the FDH enzymatic activity.36 In the present study, we have demonstrated metabolic alterations induced by this enzyme and evaluated the role of p21 in cytotoxic effects of FDH on cancer cells.
We have previously shown that FDH induces expression of p21 in a p53-dependent manner in A549 cells.31 The overall response to FDH in p53-positive cells was G1 arrest and apoptosis. To determine whether p21 is acting as an antiapoptotic or proapoptotic signal in response to FDH, we first investigated the effect of FDH expression in Tet-On A549/FDH cells31 with knocked-down p21. The p21 knockdown was achieved using a siRNA approach with p21-specific short-chain oligonucleotides (Table 1). We simultaneously transfected Tet-On A549/FDH cells with p21-targeted siRNA and induced FDH expression with doxycycline.31 In agreement with our published studies,31 in control nontransfected cells or cells transfected with scrambled siRNA, we observed the appearance of p21 protein 24 hours after FDH induction, with its further graduate elevation between 24 and 72 hours after FDH induction (Fig. 1). In contrast, transfection of FDH-expressing cells with p21-targeting siRNA resulted in a significant decrease in p21 mRNA and protein levels, observed as early as 24 hours after transfection, with the indication of a more complete p21 knockdown at 48 and 72 hours (Fig. 1A and and1B).1B). Of note, equal levels of FDH expression in control, scrambled, and siRNA transfected cells were demonstrated in these experiments (Fig. 1B).
As expected, p21 silencing prevented G1 arrest in response to FDH (Fig. 1C), confirming that FDH-induced folate stress leads to the arrest through p21 as a downstream target. In contrast, apoptosis was seen in p21-deficient as well as p21-proficient cells (Fig. 1D). Calculation of the number of apoptotic cells revealed that, in response to FDH, p21-deficient cells exhibited enhanced apoptosis at the earlier time point compared to p21-expressing cells, with about 1.5-fold increase in apoptotic cells at 48 hours after FDH induction (Fig. 1E). Interestingly, this difference became much smaller at 72 hours after the FDH induction (about 1.2-fold increase in p21-deficient cells), indicating a strong apoptotic response in both p21-proficient and p21-deficient cells (Fig. 1D and and1E1E).
To further investigate the effects of FDH in p21-deficient cells, we transiently expressed FDH in HCT116 and HCT116 p21−/− cells. Expression of FDH induced the expression of the p21 protein in HCT116 cells, whereas HCT116 p21−/− cells lack such capabilities (Fig. 2A). Analysis of the apoptotic cell population by annexin V/PI staining (Fig. 2B) demonstrated that FDH expression results in a significant increase in apoptotic cells at 24 and 48 hours after FDH transfection in HCT116 p21−/− cells as compared to p21-positive HCT116 cells (Fig. 2C). Remarkably, by 72 hours after FDH transfection, HCT116 p21+/+ and HCT116 p21−/− cells show little difference in the number of apoptotic cells (Fig. 2C).
We have previously reported that FDH induces G1 arrest in A549 cells, which we attributed to the p21 activation.31 In the present study, such an arrest was not seen in p21 knocked-down cells (above), which provides direct evidence for the p21-dependent G1 arrest in FDH-expressing cells. To confirm this functional association between FDH and p21, we evaluated the distribution of HCT116 cells (p21+/+ and p21−/−) between cell cycle phases in the absence and presence of FDH. Surprisingly, we have observed that in HCT116 p21+/+ cells, FDH induced strong G2 arrest instead of G1 arrest seen in A549 cells (Fig. 2D). Furthermore, this arrest was not seen in p21-deficient (HCT116 p21−/−) cells (Fig. 2D).
The above data suggested that p21 functions to prevent FDH-induced apoptosis without direct participation in apoptotic signaling. To confirm these findings, we studied whether the p53 downstream target PUMA, which is also up-regulated in response to FDH, is solely responsible for p53-dependent FDH-induced apoptosis. Toward this end, we investigated the effects of PUMA knockdown on FDH-induced apoptosis in Tet-On A549/FDH cells. Utilizing a PUMA-specific siRNA (Table 1), we were able to abolish the expression of PUMA mRNA and protein in response to FDH expression at 48 and 72 hours after siRNA transfection (Fig. 3A). We further observed that cells with knocked-down PUMA were not sensitive to FDH: FDH expression in cells transfected with scrambled siRNA caused approximately 50% of the cell population to stain positive for annexin V 48 hours after doxycycline addition, whereas cells transfected with PUMA siRNA showed very little annexin V staining (Fig. 3B and and3C).3C). While p21 only partially and temporarily protects cells against FDH-induced apoptosis, the PUMA knockdown provides complete and permanent protection. Thus, these data highlight PUMA as a main downstream effector of FDH-induced apoptosis in p53-proficient cells.
G1 or G2 arrest is a common cellular response to DNA damage.37 These arrests can be also activated by nucleotide pool deprivation.38-40 We have evaluated DNA damage in A549 and HCT116 cells upon FDH expression by assessing the levels of histone H2AX phosphorylation. These experiments indicated that DNA damage does not take place in response to FDH elevation (Fig. 4A). In contrast, the ATP pool was decreased about 2- and 30-fold after FDH induction in A549 and HCT116 cells, respectively (Fig. 4B). This was in agreement with our previous report36 and with the fact that FDH should deplete 10-formyltetrahydrofolate, a substrate for two reactions of the de novo purine biosynthesis. To further confirm that FDH does not cause DNA damage, we also carried out a comet assay41 in A549 cells with and without FDH induction. This assay evaluates single- and double-stranded DNA breaks based upon the ability of denatured, cleaved DNA fragments to migrate out of the nucleoid under the influence of an electric field. No DNA damage upon FDH expression was observed in these experiments compared to cells positive for comet tails (Fig. 5).
A strong decrease in 10-fTHF was observed in both cell lines upon FDH expression. While in A549 cells this decrease was 4-fold, in HCT116 cells, 10-fTHF was depleted to the undetectable levels upon FDH expression (Fig. 6). Of note, the levels of 10-fTHF in HCT116 cells were initially much lower (about 30-fold) than in A549 cells (Fig. 6). Alongside with 10-fTHF, another folate pool, 5-mTHF, was also significantly decreased in response to FDH (2-fold and 6.5-fold, respectively, for A549 and HCT116 cells) (Fig. 6A and and6B).6B). This is in agreement with the notion that FDH decreases folate-bound one-carbon groups (Fig. 6C).32 Changes in the THF/5,10-methylene-THF pool were insignificant in both cell lines (Fig. 6). Overall, while the levels of reduced folate pools are different in A549 and HCT116 cells (with the former having almost 2.5-fold higher total folate), changes in intracellular folates in response to FDH showed a similar trend in both cell lines including the decrease of the total folate pool.
We have investigated subcellular localization of p21 in response to FDH by confocal microscopy. In both A549 and HCT116 cell lines, strong nuclear accumulation of p21 was observed (Fig. 7). Such an accumulation is in agreement with the function of p21 in the regulation of the cell cycle.42 These experiments indicated that in both cell lines, upon FDH expression, p21 accumulated in nucleoli. This observation, which is in line with earlier reports,43,44 was further confirmed by double labeling of cells for p21 and the nucleolar protein, fibrillarin.44 Of note, much less profound accumulation of p21 was also seen in the cytoplasm (Fig. 7).
Our early studies have shown that FDH activates p53-dependent G1 arrest and apoptosis in rapidly proliferating cancer cells,31,36 which perhaps explains down-regulation of the protein in many cancers.34 FDH elevation is accompanied by the increased levels of p21 and PUMA.31,36 PUMA, a proapoptotic BH3-only member of Bcl2 family proteins, is considered as one of the main downstream effectors of p53 in apoptosis induction.45,46 In turn, p21 is a well-known downstream target of p53 in G1 arrest.15 In addition, numerous reports imply a role of p21 as a proapoptotic or antiapoptotic effector.13,15-17 While mechanisms by which p21 can promote apoptosis are not clear, the inhibition of apoptosis by p21 can be either direct (through the binding to key apoptotic molecules) or indirect (in cases when progression through the cell cycle is required for apoptosis).16,17 Thus, the function of p21 in apoptosis may or may not be related to its role in the cell cycle control.16,17 In the present study, we have addressed the role of p21 in FDH antiproliferative effects.
If p21 would play a proapoptotic role, direct or indirect, in the cellular response to FDH, its knockdown could be expected to inhibit FDH-induced apoptosis, which was not the case in our experiments. Instead, A549 cells become more sensitive to FDH upon treatment with p21-specific siRNA. This was reflected in an early apoptosis onset apparently due to the lack of the G1 arrest–dependent delay of the cellular response in p21-deficient cells. In addition, p21 could potentially slow down cellular response to FDH by inhibiting procaspase-347 or SAPK,48,49 FDH downstream effectors in apoptosis induction.31,50 In contrast, the silencing of PUMA by siRNA completely protected A549 cells from FDH-induced apoptosis, indicating that this protein is a key effector in this process. The effect of p21 deletion was even more profound in another cell line, HCT116. Thus, at early time points (24 and 48 hours after FDH transfection), two-fold more p21-deficient cells undergo apoptosis than in the case of p21-positive cells. The more profound effect in HCT116 cells could be attributed to the fact that in HCT116 p21−/− cells, the p21 gene was deleted through homologous recombination, which ensures the complete knockout.8
The enhanced apoptotic response to FDH in HCT116 p21−/− compared to p21+/+ cells could be also explained by the fact that in the HCT116 cell line, FDH induces G2 but not G1 arrest as in A549 cells. As an inhibitor of Cdk1 phosphorylation, p21 can be involved in both G1 and G2 cell cycle arrest.15 Together with GADD45 and 14-3-3s, the p21 protein is responsible for the maintenance of G2 arrest through effects on the cyclin B1-Cdk1 complex.51 Moreover, it has been suggested that G2 arrest and the induction of apoptosis are two parallel processes directed by the levels of p21.17,18 Of note, levels of p21 in response to FDH were lower in HCT116 p21+/+ than in A549 cells. Such levels might be insufficient to induce G1 arrest. While the role of p21 in G2 arrest is well appreciated in the literature, this arrest can be also p21 independent. Thus, in response to the proteasome inhibitor MG132, HCT116 cells undergo G2 arrest independent of p53 or p21 status.52 However, although cells lacking p53 or p21 can still undergo G2 arrest in response to DNA damage, the p21 protein (activated by p53) is essential in sustaining the G2 arrest.10 In support of the role of p21 in FDH-induced G2 arrest in HCT116 cells, the isogenic cell line, HCT116 p21−/−, did not undergo arrest upon FDH elevation.
In a stress response, the proportion of cells that arrest at G1-S or G2-M depends on cell type, growth conditions, and the checkpoint controls operative in the cell.10 For example, paclitaxel induces p53 and p21 in A549 cells, causing G1 and G2 arrest, but HCT116 cells do not up-regulate p53 in response to this drug.53 Paclitaxel, however, is not a DNA-damaging agent, while the best-known example of G2 checkpoint activation is by DNA damage.51 Folate deficiency, on the other hand, is known to induce DNA damage.54 The underlying mechanism is an increased misincorporation of uracil into DNA at conditions of insufficient TMP biosynthesis, a folate-dependent reaction.55 Of note, the elevation of FDH could produce, to some extent, similar effects on the intracellularly reduced folate pool as folate deficiency. This phenomenon is associated with the fact that the enzyme depletes folate-bound one-carbon groups (Fig. 6C), while folate deficiency decreases the group carriers. The outcome toward folate-dependent biosynthetic reactions could be similar with both insults. Our study, however, demonstrated that the FDH induction does not lead to DNA damage. Instead, it severely depletes intracellular purine pools,36 which in turn should inhibit DNA and RNA synthesis. Of note, depletion of intracellular ribonucleotides, but not deoxyribonucleotides, has been shown to reversibly activate p53,39 the effect also seen in FDH-expressing cells.36 Changes in reduced folate pools provide an explanation for the lack of DNA damage in response to FDH elevation: the 10-fTHF pool responsible for purine biosynthesis was dramatically depleted, but the 5,10-methylene-THF/THF pool, part of which is responsible for TMP biosynthesis, stays at about the same level (Fig. 6A and and6C6C).
Interestingly, while the purine depletion in response to FDH was profound (as judged by ATP levels) in both A549 and HCT116 cell lines, the cell cycle arrest took place at different checkpoints, G1 and G2, respectively. The p21-dependent G1 arrest in response to nucleotide deprivation is a common phenomenon to prevent entering S phase, in which DNA biosynthesis requires an abundant supply of nucleotides. It is not completely clear at present why FDH induces p21-dependent G2 arrest in HCT116 cells. In this regard, it is known that G2/M cyclines are subject to inhibition by growth-restricting conditions.51 Therefore, withdrawal of crucial nutrients, such as folate, could be expected to result in this type of arrest. In support of this view, G2 arrest in HepG2 cells in response to folate withdrawal has been demonstrated.56 In line with this mechanism, the present study has demonstrated the overall decrease in intracellularly reduced folate pools in response to FDH expression. The activation of different checkpoints in two cell lines could be associated with the fact that HCT116 cells are mismatch repair (MMR) deficient.57 In this regard, different effects of folate depletion on MMR-proficient and -deficient cells have been reported, with MMR-deficient cells being resistant to apoptosis induced by folate withdrawal.58 This mechanism, however, might not be relevant to FDH effects because strong apoptosis was observed in FDH-expressing HCT116 cells (Fig. 2).
The cell cycle regulatory function of p21 is associated with its nuclear localization, but the protein can also localize in the cytoplasm.5 While p21 does not have a nuclear export signal, the phosphorylation near its nuclear localization signal (NLS) retains the protein in the cytoplasm.59 Another mechanism to retain p21 in the cytoplasm, which is the truncation of the NLS-containing C-terminus by specific proteases, has also been reported.60 In the nucleus, in addition to the regulation of the cell cycle progression, p21 is also involved in a variety of transcriptional responses.44 In the cytoplasm, p21 can initiate antiapoptotic responses by inhibiting proapoptotic kinase ASK142 or by binding to procaspase 3, thus preventing its proteolytic activation.47 In a more general sense, it has been suggested that the subcellular localization of p21 defines its function as a tumor suppressor (nuclear localization) or oncoprotein (cytoplasmic localization).44 Indeed, some human cancers display elevated levels of cytoplasmic p21, which is associated with poor prognosis.61-65 In response to FDH, p21 accumulates in the nuclei of both A549 and HCT116 cell lines, with strongest accumulation seen in nucleoli (Fig. 7), which is in agreement with the cell cycle arrest observed in our studies.42-44 While some accumulation in the cytoplasm was also seen, the role of cytoplasmic p21 in FDH effects is not clear. Interestingly, we have recently shown that FDH inhibits motility by affecting the cofilin/actin pathway.66 In this regard, effects of cytoplasmic p21 on cellular motility, through inhibition of ROCK kinase (an upstream effector in the LIMK/cofilin/actin pathway), were reported.67,68 Whether the cytoplasmic accumulation of p21 is a cellular attempt to counteract effects of FDH on motility is a subject for future studies.
Overall, our data suggest that activation of p21-dependent G1 or G2 cell cycle arrest counteracts the FDH-induced apoptotic response (Fig. 8). In support of this mechanism, the lack of p21 sensitizes cells to FDH, resulting in an earlier onset of the apoptosis. This conclusion is in line with the observation that p21 attenuates apoptotic signals in methotrexate-treated cells.69 Of note, both methotrexate and FDH work in the same direction with regard to folate metabolism, inhibiting folate-dependent biosynthetic reactions. The activation of p21, however, is not sufficient to rescue cells from FDH-induced apoptosis.
Cell culture media were purchased from Mediatech (Manassas, VA), and fetal bovine serum was purchased from Atlanta Biologicals (Lawrenceville, GA). Tet-certified fetal bovine serum was obtained from Clontech (Mountain View, CA). Tet-On A549/FDH cells were generated in our previous studies.31 HCT116 and HCT116 p21−/− cell lines, a gift from Dr. Bert Vogelstein (The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine), were grown in RPMI 1640 culture media supplemented with 10% (v/v) fetal bovine serum at 37°C under humidified air containing 5% CO2.
HCT116 cells (~1.0 × 106) were transfected with 2 µg pcDNA3.1 or pcDNA3.1/FDH plasmid using Amaxa nucleofector kit “V” (Lonza, Basel, Switzerland) according to the manufacturer’s protocol.
Tet-On A549/FDH cells (1.2 × 105) were transfected with 25 nmol of Stealth RNAi (Invitrogen, Carlsbad, CA) (Table 1) using 5 to 10 µL Lipofectamine 2000 (Invitrogen). Scrambled Stealth RNAi (Invitrogen) was used as a negative control. Transfection was performed following the manufacturer’s protocols. Total RNA was purified with RNA Easy Mini Kit (Qiagen, Hilden, Germany). Reverse transcriptase reaction was performed with an Oligo (dT)18 primer using Advantage RT-for-PCR Kit (Clontech). Conventional PCR was carried out using specific primers (Table 1) and Pfu-turbo DNA polymerase (Stratagene, La Jolla, CA).
Cell lysates were prepared in buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS, 1 mM PMSF, and mammalian protease inhibitor cocktail (Sigma, St. Louis, MO). Lysates were subjected to SDS-PAGE followed by immunoblot with specified antibodies. Expression of FDH protein was verified with an in-house FDH-specific polyclonal antibody (1:10,000).31,34,36 p21 was detected using a p21-specific monoclonal antibody (5 µg/mL) (Sigma). A polyclonal PUMA antibody was used to detect PUMA (1:1,000) (Cell Signaling Technology, Danvers, MA). Actin was detected using a monoclonal antibody from Calbiochem (1:8,000) (La Jolla, CA).
Cell cycle analysis was carried out using propidium iodide staining/FACS. Cells (1.0 × 106) were washed once with cold PBS and centrifuged at 1,000 rpm for 5 minutes. Pellets were resuspended in 200 μL of cold PBS, fixed by the addition of 4 mL of 70% ethanol, and incubated overnight at −20°C. Following centrifugation, samples were resuspended in 500 μL of PBS containing 40 μg/mL propidium iodide and 100 μg/mL Rnase (both from Roche, Basel, Switzerland), incubated for 30 minutes at 37°C, and analyzed by FACS. Apoptotic cells were detected by annexin V and PI labeling using Annexin V-FLUOS staining kit (Roche). All cells (floating and attached) were used in these experiments. Samples were analyzed at the flow cytometry core facility at Hollings Cancer Center.
DNA damage assays were performed using the EpiQuik In Situ DNA Damage Assay Kit (Epigentek, Farmingdale, NY). This assay measures the phosphorylation at serine 139 of histone H2AX, which is one of the earliest chromatin modification events in DNA damage response. All experiments were performed following the manufacturer’s protocols.
DNA strand breaks were assessed using Alkaline Comet Assay kit (Trevigen, Gaithersburg, MD). All experiments were preformed following the manufacturer’s protocols. Images were captured using a Zeiss Axio Observer D1 multichannel fluorescent microscope (Oberkochen, Germany).
ATP levels were measured using ATP Bioluminescence Assay Kit CLS II (Roche) following the manufacturer’s protocols as we previously described.36
Approximately 5 × 106 cells were collected and rapidly washed 3 times with ice-cold PBS. The cell pellet was resuspended in 50 mM Tris-HCl buffer, pH 7.4, containing 50 mM sodium ascorbate. Cells were lysed by heating for 3 minutes in a boiling water bath. Cell lysates were chilled on ice and centrifuged for 5 minutes at 17,000g at 4°C. Folate pools were measured in cell lysates by the ternary complex assay method70 as we previously described.71 Folate levels were calculated per milligram of cellular protein measured by the Bradford assay.
Cells seeded in Lab-Tek II Chamber (Nalge Nunc International, Penfield, NY) were fixed with 3.7% of methanol-free formaldehyde for 10 minutes and permeabilized with 0.1% Triton X-100 for 5 minutes. After blocking with 10% preimmune goat serum in PBS for 45 minutes, slides were incubated with p21-specific monoclonal antibody (1:200) (Pharmingen, San Diego, CA) for 1 hour at room temperature. This was followed by incubation with secondary goat anti-mouse antibody labeled with Alexa Fluor 488 (Life Technologies, Grand Island, NY) in a dark chamber for 45 minutes at room temperature. Nuclei were counterstained using To-Pro3 (Life Technologies, Grand Island, NY). Nucleoli were visualized by staining with fibrillarin polyclonal antibody (1:100) (Abcam, Cambridge, UK) and secondary antibody conjugated with Alexa Fluor 555 (Molecular Bioprobes). Images were captured and processed using a Leica TCS SP2 AOBS scanning confocal microscope (Wetzlar, Germany) at the imaging core facility at Hollings Cancer Center.
The authors thank Dr. Bert Vogelstein for the kind gift of HCT116 p21−/− cells.
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
This work was supported in part by the National Institutes of Health [grant numbers DK54388 and CA095030]. Flow cytometry and imaging core facilities were supported in part by the Cancer Center [grant number P30 CA138313] to the Hollings Cancer Center, Medical University of South Carolina. L.A.X. was supported by an Abney Foundation scholarship.